Including a spectrum of activity against Gram-negative pathogens versus other BL/BLI4–16
Discover more about HAP/VAP in a clinical setting.
Listen to our ‘Infectious Thinking’ podcast on Spotify, as top medical experts discuss the challenges of MDR infections in high-risk patients.
ESBL/CRE
Enterobacterales/
P. aeruginosa
MDR P. aeruginosa/
XDR P. aeruginosa
Tab Number 4
Tab Number 5
Adapted from Sader HS, et al. 2020 and supplementary information17
Adapted from Sader HS, et al. 2020 and supplementary information17
Adapted from Sader HS, et al. 2020 and supplementary information17
ZAVICEFTA is active against a broad range of Gram-negative resistance mechanisms, including class A (e.g. ESBL and KPC), class C (e.g. AmpC) and some class D¶ (including OXA-48) β-lactamases.4
Footnotes:
Abbreviations:
References:
Dette nettstedet er kun for helsepersonell.
Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.
Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.